In a regulatory filing, the company states: “On August 20, 2025, Aaron Ondrey resigned as Chief Financial Officer of Rocket Pharmaceuticals (RCKT), effective September 5, 2025, to pursue other opportunities. On August 25, 2025, Martin Wilson, the Company’s General Counsel and Chief Corporate Officer and the Company’s Corporate Secretary, was appointed as the Company’s interim Principal Financial Officer, effective September 8, 2025. Mr. Wilson joined the Company as General Counsel and Chief Compliance Officer in November 2021 and became Chief Corporate Officer in March 2024.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- EMA says Rocket Pharmaceuticals withdraws MA application for Fanskya
- Hold Rating on Rocket Pharmaceuticals Amid Uncertainties in RP-A501 Study Resumption
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Bank of America Upgrades Rocket Pharma Stock (RCKT) After FDA Lifts Clinical Hold on Danon Disease Trial
- Cautious Optimism for Rocket Pharmaceuticals Amid Adjusted RP-A501 Trial Protocol